- Details
- Mary-Ellen Taplin presents on the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC) after docetaxel or AR pathway inhibitors in the metastatic hormone-sensitive prostate cancer (mHSPC) setting. There are currently no prospective clinical trial data to guide the optimal selection of treatment for first-line mCRPC after ADT/docetaxel or ADT/AR-inhibition. Dr. Taplin exp...
|
- Details
- The aim of this presentation by Gerhardt (Gert) Attard at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 was to provide the research community with the information required to make the right choice on the dose and regimen of prednisone to combine with abiraterone and indications for combining dexamethasone with abiraterone, how to maximize therapy of steroids with abiraterone aceta...
|
- Details
- During the Management of Metastatic Castration-sensitive/naive Prostate Cancer session at the 2019 Advanced Prostate Cancer Consensus Conference, William Oh presented the use of androgen deprivation therapy (ADT) alone vs. the use of ADT in addition to one of the available systemic therapies for metastatic prostate cancer. Biography: William K. Oh, MD, Chief Medical Officer (CMO), of the Prostate...
|
- Details
- During the Management of metastatic castration-sensitive/naive prostate cancer session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC), Matthew Sydes presented a statisticians' perspective on Addition of AR pathway inhibitors vs. docetaxel. Video Length 10:53 minutes Biography: Matthew R Sydes, MSc CStat CSci, MRC Clinical Trials Unit at UCL London Related Content: Written Confer...
|
- Details
- Chris Sweeney, MD and Mary-Ellen Taplin, MD discuss their current approach to treating patients with metastatic hormone-sensitive prostate cancer (mHSPC). Dr. Sweeney first evaluates whether or not the patient is fit for chemotherapy and what their access is to abiraterone which both have a clear benefit in high volume disease. Based on the CHAARTED data, Dr. Taplin does not offer chemotherapy in...
|
- Details
- Petros Grivas invites Neeraj Agarwal to discuss the TITAN trial which reported the first interim analysis at ASCO 2019. The TITAN trial is a "Study of Apalutamide Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With metastatic hormone-sensitive prostate cancer (mHSPC). A total of 525 patients were assigned to receive apalutamide plus ADT and 527 to receive placebo plus ADT. The...
|
- Details
- Kim Chi, MD discusses the first results from TITAN, A phase 3 randomized, placebo-controlled, double-blind study of apalutamide (APA) versus placebo (PBO) in men with metastatic hormone-sensitive prostate cancer (mHSPC), with Michael Morris, MD, and Alicia Morgans, MD. TITAN was designed to accrue patients with prior treatment for localized prostate cancer or prior docetaxel for mHSPC were allowed...
|
- Details
- Mary-Ellen Taplin and Alicia Morgans discuss treatment strategies in newly diagnosed metastatic prostate cancer patients. They review trial results and upcoming data that is expected to be reported out in the near future. Monotherapy with ADT is no longer the standard of care. They also discuss sequencing strategies in men who have progressed on therapy. Biographies: Mary-Ellen Taplin, MD, Chair,...
|
- Details
- Alicia Morgans, MD reviews her recent presentation in a conversation with Charles Ryan, MD. Her presentation covers three main topics including systemic therapies, treatment of the primary, and metastases directed therapy. The three main goals of therapy include delay time to progression, delay the other important goals, delay time to initiation of systemic therapy, and ultimately cure, especially...
|
- Details
- Alicia Morgans presents a lecture on the contemporary management strategies for hormone sensitive prostate cancer with a focus on systemic therapy including chemohormonal approaches and the use of abiraterone for metastatic hormone sensitive disease. In the discussion, Alicia compares and contrasts both the CHAARTED and STAMPEDE data and provides an update on treatment today, including evidence ba...
|
